At 5-30 mg AM (Dylan-archetype dose range):

• Onset: detectable subtle effect within ~30-60 min on first dose; full subjective profile takes 5-14 days of consistent dosing to express (chronic-upregulation mechanism). Single doses are often described as "barely noticeable."
• Peak window: ~2-4 h post-dose; tapers over 4-6 h matching the half-life.
• Characteristic effects (per consistent user reports):
  • Mild anxiolytic — the dominant effect. "Mental quiet," reduced reactivity to social/work stress, less rumination. Not sedating — clearheaded calm rather than benzodiazepine-like.
  • Motivation: neutral. Does not increase drive, does not blunt it. Distinct from anxiolytics that flatten affect (some SSRI patterns) — fasoracetam users typically retain emotional range.
  • Cognitive smoothing rather than enhancement. Easier to think clearly under load, but no acute focus surge or working-memory boost. Subtle background effect.
  • No euphoria, no stimulation, no tolerance crash. Genuinely "background" pharmacology.
• What it does NOT do (despite some marketing copy): does not increase deep-work output the way pramiracetam/phenylpiracetam are reported to; does not produce mood elevation the way aniracetam is reported to; does not provide acute stress-resilience the way ashwagandha or selank do; does not enhance motivation the way bromantane or low-dose modafinil do.
• Variability: very high. Some users report no effect at any dose; some report meaningful anxiolytic effect at 5-10 mg; the "responder rate" appears to be roughly 40-60% based on forum reports, consistent with the genotype-specific mechanism (mGluR-network mutation carriers more likely to respond).

Honest summary for Dylan: at 5-30 mg AM, expect a subtle background anxiolytic over 1-2 weeks, with no acute "feel," no motivation effect, no cognitive surge. If you don't notice anything by week 3 of consistent dosing, you're probably a non-responder. Clean to discontinue at this low dose range — withdrawal concerns are dose- and duration-dependent.

• Tolerance buildup: minimal at low biohacker doses, modest at clinical doses. No tolerance documented in the Elia 2018 study (4 weeks at 400 mg BID); biohacker reports at 10-30 mg suggest stable response over weeks. The chronic-upregulation mechanism actually increases response over the first 1-2 weeks for most responders.
• Recommended cycle: 5 days on / 2 days off is the biohacker convention (Wholistic Research, Mind Lab Pro, etc.), but the half-life and chronic-upregulation mechanism mean this pattern doesn't meaningfully reset receptor density. A more defensible pattern: 2-4 weeks on / 1-2 weeks off for any consistent-dosing protocol, or pure PRN dosing (every-few-days only) to avoid the upregulation pattern entirely.
• Reset protocol if needed: 2-week off-drug window for full receptor-density normalization based on rat data. Taper 20→10→5→0 mg over 5-7 days if used daily >2 weeks to mitigate rebound anxiety.

Synergistic with

• citicoline 500 mg (Dylan's V4 daily) — fasoracetam upregulates cortical ACh release, citicoline provides choline substrate. Mitigates the headache/brain-fog pattern reported by some users. Already in Dylan's stack — no additional action needed.
• alpha-GPC 300 mg — alternative choline donor, more bioavailable for ACh synthesis. Stack only if not already on citicoline.
• L-theanine 200 mg — already in Dylan's V4. Theanine adds AMPA/glutamate-system modulation in the calming direction and is the classic anxiolytic-stack partner. No documented interaction with fasoracetam, mechanistically convergent for anxiolysis.
• rhodiola 250 mg — already in Dylan's V4. Adaptogenic anxiolytic with distinct mechanism (HPA-axis, monoamine modulation). Convergent goals, distinct receptors, no documented interaction.
• magnesium glycinate / threonate — both in Dylan's V4. Magnesium is a low-affinity NMDA modulator and GABA-A potentiator; theoretically convergent on the calming-glutamate / enhanced-GABA axis fasoracetam targets.

Avoid stacking with

• phenibut — HARD AVOID. Documented near-fatal case report: bradycardia HR=36, GCS=3, GABA-B rebound psychosis on day 2. Mechanism: fasoracetam GABA-B upregulation amplifies phenibut GABA-B agonism. Do not use concurrently at any dose, do not use within 2 weeks of phenibut discontinuation.
• picamilon — niacin-conjugated GABA, GABA-B activity. Same upregulation-amplifies-agonism logic as phenibut. Avoid concurrent.
• GHB / GABA-B agonists generally — same mechanism; not relevant for Dylan but worth flagging.
• TAK-653 — both modulate the glutamate system. Fasoracetam upregulates mGluR autoreceptors (presynaptic brake); TAK-653 amplifies AMPA-receptor activity (postsynaptic agonist potentiation). Mechanistically opposing in some respects, convergent in others — net effect unpredictable. Hold one during a trial of the other.
• neboglamine — NMDA glycine-site PAM. Glutamate-system modulator in a different direction. Avoid stacking with fasoracetam during a trial of either compound (signal disambiguation + multiplied unknowns).
• memantine — NMDA antagonist. Mechanism partially opposed to fasoracetam's mGluR-upregulation pattern. No clinical data on the combination. Avoid concurrent.
• agmatine — modest NMDA antagonist + nNOS modulator. Same disambiguation concern as memantine. Hold during a fasoracetam trial.
• Other racetams (piracetam, aniracetam, pramiracetam, oxiracetam, phenylpiracetam, coluracetam, nefiracetam) — mechanism overlap is partial; no specific safety contraindications, but stacking multiple racetams produces diffuse cholinergic enhancement and complicates signal disambiguation. Run one racetam at a time during trials.
• High-dose benzodiazepines / barbiturates — additive GABAergic effect. Theoretical, not Dylan-relevant.
• Baclofen — direct GABA-B agonist. Same mechanism class as phenibut concern, less recreational potential but same upregulation-amplifies-agonism issue.

Neutral / safe co-administration (best current understanding)

• V4 OTC stack (citicoline, NAC, magnesium glycinate/threonate, fish oil/DHA, phosphatidylserine, curcumin, rhodiola, L-theanine, glycine/L-tryptophan, D3+K2, beta-alanine, vitamin C, creatine) — no flagged interaction. The cholinergic stack overlap is convergent (citicoline supports ACh demand from fasoracetam-induced ACh release).
• Modafinil 100-200 mg AM — orthogonal mechanism (DAT/NET, histaminergic, orexinergic vs glutamate/GABA/cholinergic). No documented interaction. Theoretically modafinil's stimulation could partly cancel fasoracetam's anxiolysis, but mechanisms are distinct — many biohacker reports of stacking the two without issue.
• Bromantane 50 mg AM — DA-synthesis upregulation, no direct overlap with fasoracetam mechanism. Reasonable stack-mate for someone wanting cognitive enhancement + anxiolysis.
• Adamax / Semax / Selank (Russian peptides) — distinct mechanisms (regulatory peptides, BDNF/DA modulation). No documented interactions.
• BPC-157, TB-500, GHK-Cu (peripheral peptides) — different system entirely, no interactions.
• Cerebrolysin — neurotrophic peptide cocktail, BDNF/NGF mimicry. No documented interaction with fasoracetam; mechanistically distinct.

• CYP enzymes: fasoracetam is largely renally cleared as unchanged parent, with minimal hepatic metabolism. Therefore, minimal CYP-mediated drug-drug interactions expected. No published CYP3A4/2D6 inhibition or induction data.
• Renal-clearance interactions: drugs that affect renal tubular secretion (probenecid, NSAIDs at chronic high dose, some antibiotics) could theoretically alter fasoracetam clearance. Not clinically documented. Not relevant for Dylan's stack.
• Oral contraceptives: no documented interaction (no CYP3A4 induction expected from a renally-cleared compound).
• Antidepressants (SSRI/SNRI): no documented interaction. Some biohacker reports of stacking fasoracetam with SSRIs without issue. Mechanistically distinct.
• Stimulants (amphetamine, methylphenidate, modafinil): no documented interaction. The chronic-upregulation mechanism does not predict acute interaction with monoamine releasers.
• Alcohol: GABA-B upregulation may modestly enhance sedative effects of alcohol. Not clinically characterized; biohacker convention is to avoid heavy alcohol on fasoracetam. Not relevant for Dylan (zero alcohol baseline).

• GRM1, GRM2, GRM3, GRM5, GRM7, GRM8 (mGluR1, 2, 3, 5, 7, 8 receptor genes) — the central PGx hypothesis for fasoracetam efficacy. Elia 2018 selected adolescents with mGluR network mutations specifically and reported genotype-specific response. ASCEND tested this hypothesis in a controlled setting and failed to replicate — even the genotype-positive arm did not separate from placebo. Net status: the genotype-specific responder hypothesis is not validated by controlled-trial data. Worth checking 23andMe results in June 2026 for any clear loss-of-function variants in the mGluR network, but absence does not predict response failure (and presence does not predict success — see ASCEND).
• 22q11.2 deletion — the active Nobias indication. Not relevant to Dylan (no 22q11.2DS).
• CYP2D6 / CYP3A4 polymorphisms: minimal clinical impact expected given renal-clearance dominance.
• Practical: pharmacogenomic data is the single open question that could refine the verdict. Worth re-checking after Dylan's 23andMe results land in June 2026 — specifically looking for any reported pathogenic/likely-pathogenic variants in GRM1-8 or downstream glutamatergic signaling genes (GRIA1-4, GRIN1-2B, SHANK3, etc.). Absence of such variants pushes verdict toward SKIP-FOR-NOW; presence of clear variants would tilt toward STRONG-CANDIDATE pending Phase 3.

Cost estimate (Dylan use case, 10-20 mg AM PRN, ~10-15 doses/month): ~$25-50/month, well under the $40 V5-additions ceiling. PRN use makes this one of the more cost-efficient additions.

Critical sourcing notes:

1. Powder format requires analytical balance for accurate 5-30 mg dosing. Volumetric dosing (dissolving in distilled water for ~1 mg/mL) is a workable alternative.
2. CAS verification — fasoracetam CAS 110958-19-5. Vendor copy that omits CAS number is a red flag.
3. Identity check at higher doses — at 30+ mg/day the margin for mislabeling becomes more relevant. COA verification is recommended.
4. Customs / legal — fasoracetam is not scheduled in the US (Schedule 4 / Rx-only in Australia, no equivalent US restriction). Personal-import legality is gray-area but US FDA generally does not pursue research-chem personal use. Possession/use at user's risk.

Baseline (before starting)

• GAD-7 (anxiety) + PHQ-9 (depression) — if anxiety is the target, establish 2-week pre-baseline.
• Subjective cognitive output (deep-work session count, sales-call quality, sparring read) — 2-week pre-baseline.
• Sleep onset latency, sleep quality, sleep duration — Oura/Whoop, 2-week pre-baseline.
• Resting heart rate, blood pressure — basic cardiovascular safety.
• Liver panel, CBC, BMP (especially serum creatinine for renal clearance) — baseline before any novel research-chem with renal-dominant clearance.
• 23andMe mGluR-network gene status (when results land June 2026) — GRM1-8, GRIA1-4, GRIN1-2B, SHANK3 variants. Predictive of responder phenotype; absence doesn't preclude response but presence increases prior probability.

During use (week 2-4)

• GAD-7 + PHQ-9 weekly.
• Subjective cognitive/training output weekly.
• Sleep metrics daily.
• HR/BP weekly.
• Subjective: any GI distress, headache pattern, mood drift, sleep changes, training subjective changes.

Post-cycle / discontinuation watch

• GAD-7 + PHQ-9 at days 3, 7, 14 post-discontinuation — rebound anxiety watch.
• Sleep onset latency — rebound insomnia is an early-discontinuation signal.
• Subjective irritability / mood drift — chronic-dosing rebound pattern.